Los puntos clave no están disponibles para este artículo en este momento.
Supplementary Figure S7. BCMA CAR-T Therapy Attenuates BAFF/GALECTIN/MK Pathway-mediated Immunosuppression and Activates MIF Pathway-mediated Anti-MM Immunity.
Yang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: